Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development

Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC).Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development

Photo grabbed from Roivant Sciences website

Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase. Additionally, the safety profile observed in IDEAL was consistent with previously reported studies and raised no new concerns. The study results affirm Livdelzi as the first and only PBC treatment with statistically significant reductions in disease markers and pruritus versus placebo.

The study results make the case for Gilead Sciences to target the more than 130,000 Americans struggling with PBC, a chronic autoimmune disease. Livdelzi has already received FDA accelerated approval for the treatment of PBC.

On the other hand, the US Food and Drug Administration has approved Hepcludex, a Gilead Sciences therapy for the treatment of hepatitis delta virus. The approval marks an important milestone in the treatment of a rare and severe liver infection.

Additionally, Gilead Sciences boasts of an impressive dividend growth history, having initiated quarterly dividends in 2015. It pays an annualized dividend of $3.28 per share, translating to a yield of 2.5%.

Gilead Sciences, Inc. (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines for life-threatening illnesses. Their primary therapeutic focus areas include virology (particularly HIV and viral hepatitis), oncology (cancer), and inflammation.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 10 Best Debt-Free IT Stocks to Buy Now and 10 Best Stocks to Buy According to Billionaire Bill Gates.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments